Fresenius Medical Care AG (FMS) stock price is $21.42, down 2.39% on the day, as of Oct 20, 2026. It has a market cap of $12.49Bn and a P/E ratio of 11.42, and is classified in the Healthcare Services industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap12.49 Bn
P/E11.42
P/S1.13
Div. Yield0.00
Total Debt (Qtr)541.49 Bn
Revenue Growth (1y) (Qtr)4.16
Add ratio to table…
About
Fresenius Medical Care AG is a vertically integrated medical technology and healthcare service company providing products and services for individuals with kidney diseases. The company operates in the global dialysis market as a leading provider of dialysis services, medical devices, and renal pharmaceuticals. Fresenius Medical Care AG develops manufactures and distributes medical devices systems pharmaceuticals and products for kidney care to customers in more than 140…
Fresenius Medical Care AG is a vertically integrated medical technology and healthcare service company providing products and services for individuals with kidney diseases. The company operates in the global dialysis market as a leading provider of dialysis services, medical devices, and renal pharmaceuticals. Fresenius Medical Care AG develops manufactures and distributes medical devices systems pharmaceuticals and products for kidney care to customers in more than 140 countries. As of December 31 2025 the company operates 3601 dialysis centers in more than 30 countries worldwide serving 291902 dialysis patients. The company manages the world's largest network of dialysis centers and has 35 production sites in 19 countries. The core business focuses on delivering high quality care to people living with kidney disease around the globe through its three operating segments.
Fresenius Medical Care AG generates revenue through the sale of dialysis products and services renal pharmaceuticals and healthcare products across its three operating segments. The company receives a substantial portion of its Care Delivery revenue from the U. S. Medicare program and other government sources. Revenue is derived from dialysis treatments medical devices dialyzers hemodialysis machines peritoneal dialysis products home hemodialysis systems critical care products and renal pharmaceuticals such as erythropoietin stimulating agents iron sucrose and phosphate binders. The company also earns revenue from value-based care programs through risk-based delivery models that lower care costs by enhancing treatment quality and patient well-being. Healthcare products accounted for 22% of consolidated total revenue in 2025 with hemodialysis products peritoneal dialysis products and other healthcare products contributing to the healthcare product revenue stream.
The company operates through the following segments: Care Delivery Value-Based Care and Care Enablement.
Care Delivery encompasses the global network of dialysis clinics and includes services that address the complex healthcare needs and treatment choices for people living with kidney disease. This segment provides various forms of in-center kidney replacement therapies home dialysis therapies including peritoneal dialysis and home hemodialysis transplant referral coordination and additional services such as outpatient vascular care research sites renal pharmaceuticals practice support for nephrologists pharmacy services and renal-specific laboratory testing. In 2025 Fresenius Medical Care treated 70% of its patients in the U. S. and 30% internationally through this segment.
Value-Based Care drives innovation on the basis of risk-based delivery models that lower care costs by enhancing treatment quality and patient well-being supporting planned dialysis starts and fewer all-cause hospitalizations than the national average in the U. S. This segment leverages the company's U. S. clinic network the largest nephrologist network in the U. S. with over 2200 physician partnerships and the most widely adopted nephrology-specific electronic health record system in the U. S. Value-Based Care achieves exceptional clinical outcomes with optimal start rates over twice as high as the U. S. national average and contributes significantly to gross savings in government programs such as the Kidney Care Choices program.
Care Enablement is organized around three main therapy areas: in-center dialysis home dialysis and critical care. Each unit is responsible for the full product life cycle from ideation and creation to value generation supply chain management and service through to the end of the product's life. The segment provides medical devices for in-center hemodialysis and hemodiafiltration dialyzers concentrates for dialysate preparation solutions and granulates bloodlines water treatment systems home hemodialysis and peritoneal dialysis cyclers peritoneal dialysis solutions renal pharmaceuticals acute cardiopulmonary products apheresis products data processing and analysis systems and other medical devices. Care Enablement offers healthcare products for acute and chronic kidney organ support in more than 140 countries globally with a focus on hemodialysis and hemodiafiltration peritoneal dialysis and acute dialysis.
Fresenius Medical Care AG is a global leader in dialysis care providing treatment to about 7% of all dialysis patients worldwide and the global market leader for dialysis products with a market share of around 35% in 2025. In hemodialysis products alone the company holds over 40% of the global market share. The company produces approximately 38% of the worldwide sales volume of dialyzers for hemodialysis and around 50% of hemodialysis machines installed globally. Fresenius Medical Care holds the largest share of the home hemodialysis market with more than 75% of all patients performing home hemodialysis utilizing a dialysis machine from the company. The company's competitive advantages stem from its vertically integrated structure combining medical device engineering and manufacturing expertise with comprehensive patient care. Major competitors in the dialysis services industry include DaVita Inc. Diaverum AB B. Braun SE U. S. Renal Care Inc. and Nephrocare Health Services Limited. In the product market competitors include Nipro Corporation Toray Medical Co. Ltd. Baxter International Inc. and B. Braun SE among others.
The company serves dialysis patients hospitals and other specialized treatment clinics worldwide. Fresenius Medical Care provides dialysis services to patients in its treatment centers hospital settings and at home. The company sells most of its products to dialysis clinics hospitals and other specialized treatment clinics. Specific customer relationships include partnerships with over 2200 nephrologists in the U. S. through the Value-Based Care segment and collaborations with healthcare professionals for product distribution and service delivery. The company also serves patients undergoing acute kidney failure requiring continuous kidney replacement therapy and provides services to these patients at their bedside using portable dialysis equipment or at hospital dialysis sites.
Sector:HealthcareSector rationaleThe company is a vertically integrated provider of kidney care, generating revenue from dialysis services (Care Delivery), medical devices like hemodialysis machines (Care Enablement), and renal pharmaceuticals. Its core business is the delivery of patient care and the manufacture of medical products, both of which fall squarely within the Healthcare sector.Industries:+1 moreHealthcare ServicesHealthcare ServicesPrimaryThe company operates the world's largest network of 3,601 dialysis centers, providing in-center kidney replacement therapies and outpatient vascular care. This segment, Care Delivery, serves nearly 300,000 patients through a global network of clinics and physician partnerships.Medical DevicesMedical DevicesSecondaryThe company designs and manufactures medical devices including hemodialysis machines, peritoneal dialysis cyclers, and water treatment systems sold to hospitals and clinics globally.PharmaceuticalsPharmaceuticalsSecondaryThe company develops and markets renal pharmaceuticals, specifically mentioning erythropoietin stimulating agents, iron sucrose, and phosphate binders.Classified using BQ-MICSCIK: 0001333141
Bull & bear
Investment Thesis
▲ Bull case
Fresenius Medical Care is executing a multi-year operational transformation through the FME25+ and FME Reignite programs that is already delivering measurable efficiency gains and margin expansion, with the 10% operating income growth in Q1 FY26 and 70 basis point margin improvement signaling the early success of cost discipline and structural repositioning, despite near-term headwinds from TDAPA and clinic closures, positioning the company to sustain profitability even as temporary tailwinds fade.
The rollout of the 5008X CAREsystem and High Volume Hemodiafiltration (HVHDF) therapy represents a generational clinical and operational upgrade that is accelerating faster than expected, with over 100,000 treatments delivered in the first week of April and more than 100 clinics converted by quarter-end, creating a durable platform for improved patient outcomes, reduced hospitalizations, and longer-term volume recovery that is not yet reflected in current same-market treatment growth metrics but will drive organic growth acceleration in H2 FY26 and beyond.
Value-Based Care (VBC) is emerging as a hidden profit engine, with Q1 FY26 showing 3% organic revenue growth and significant margin expansion despite full-year guidance calling for decline, driven by prior-period contract true-ups, enhanced savings rates from FME25+ integration, and expanding adoption of AI-driven admissions risk prediction tools that have already demonstrated up to 26% reduction in missed treatments for high-risk ESRD patients, suggesting the segment may outperform expectations as scale and data analytics mature.
The company’s aggressive share buyback — completing a EUR 1 billion program in under one year versus the original two-year plan — combined with a net leverage ratio of 2.6x at the low end of its target corridor (2.5x–3.0x), reflects strong capital allocation discipline and balance sheet strength, providing flexibility to weather macroeconomic volatility while returning capital to shareholders and supporting earnings per share accretion independent of top-line growth.
Underlying Care Delivery performance, excluding the temporary TDAPA benefit, delivered approximately 6% constant currency earnings growth in Q1 FY26, driven by favorable payer mix, revenue cycle management improvements, and lower implicit price concessions, indicating that the core U.S. dialysis business is fundamentally improving despite weather-related volume disruptions and ACA subsidy expiry concerns, with management maintaining flat full-year U.S. market treatment growth guidance that implies meaningful sequential improvement through the year.
Fresenius Medical Care is executing a multi-year operational transformation through the FME25+ and FME Reignite programs that is already delivering measurable efficiency gains and margin expansion, with the 10% operating income growth in Q1 FY26 and 70 basis point margin improvement signaling the early success of cost discipline and structural repositioning, despite near-term headwinds from TDAPA and clinic closures, positioning the company to sustain profitability even as temporary tailwinds fade.
The rollout of the 5008X CAREsystem and High Volume Hemodiafiltration (HVHDF) therapy represents a generational clinical and operational upgrade that is accelerating faster than expected, with over 100,000 treatments delivered in the first week of April and more than 100 clinics converted by quarter-end, creating a durable platform for improved patient outcomes, reduced hospitalizations, and longer-term volume recovery that is not yet reflected in current same-market treatment growth metrics but will drive organic growth acceleration in H2 FY26 and beyond.
Value-Based Care (VBC) is emerging as a hidden profit engine, with Q1 FY26 showing 3% organic revenue growth and significant margin expansion despite full-year guidance calling for decline, driven by prior-period contract true-ups, enhanced savings rates from FME25+ integration, and expanding adoption of AI-driven admissions risk prediction tools that have already demonstrated up to 26% reduction in missed treatments for high-risk ESRD patients, suggesting the segment may outperform expectations as scale and data analytics mature.
The company’s aggressive share buyback — completing a EUR 1 billion program in under one year versus the original two-year plan — combined with a net leverage ratio of 2.6x at the low end of its target corridor (2.5x–3.0x), reflects strong capital allocation discipline and balance sheet strength, providing flexibility to weather macroeconomic volatility while returning capital to shareholders and supporting earnings per share accretion independent of top-line growth.
Underlying Care Delivery performance, excluding the temporary TDAPA benefit, delivered approximately 6% constant currency earnings growth in Q1 FY26, driven by favorable payer mix, revenue cycle management improvements, and lower implicit price concessions, indicating that the core U.S. dialysis business is fundamentally improving despite weather-related volume disruptions and ACA subsidy expiry concerns, with management maintaining flat full-year U.S. market treatment growth guidance that implies meaningful sequential improvement through the year.
Fresenius Medical Care’s full-year 2026 revenue guidance remains broadly flat despite Q1’s 4% organic growth, as management explicitly acknowledges that the TDAPA reimbursement tailwind — contributing approximately EUR 80 million in Q1 and expected to reverse into a significant headwind in H2 — will be offset by declining volumes and structural pressures, implying that the current earnings strength is artificial and unsustainable once the temporary benefit expires, leaving the business exposed to underlying volume stagnation.
Same-market treatment growth in the U.S. Care Delivery segment declined by 37 basis points in Q1 FY26, with management attributing only partial impact to severe weather and acknowledging persistent headwinds from mortality remaining above pre-pandemic levels, uncertain ACA subsidy impacts post-grace period, and ongoing clinic closures (64 already exited, targeting up to 100), suggesting that patient inflow challenges are structural and not merely cyclical, with no clear path to positive volume growth even as operational improvements roll out.
Care Enablement continues to face persistent and growing headwinds in China from volume-based procurement (VBP) and stricter tender requirements, with the segment’s organic revenue growth of 1% in Q1 FY26 being entirely dependent on strength outside China, while the company admitted that China represents 7–10% of Care Enablement sales and remains under pressure, with no clear timeline for re-entry into tenders or margin recovery, raising concerns about long-term viability of this growth pillar in a key emerging market.
Value-Based Care’s Q1 FY26 performance was bolstered by non-recurring prior-period contract true-ups and favorable premium rate effects, with management explicitly stating that revenue growth will “turn negative throughout the year” due to a change in accounting treatment for a large contract, and that the current profitability is unlikely to be sustained, signaling that the segment’s recent strength is a mirage driven by one-time items rather than organic momentum or scalable model validation.
The company’s operating cash flow increase of 39% in Q1 FY26 was driven primarily by favorable working capital management (EUR 133 million inflow, or nearly 60% of operating cash flow), with Martin Fischer acknowledging that adjusting for this line implies a 50% reduction in underlying operating cash flow, revealing that the apparent cash flow strength is temporary and reliant on short-term timing benefits rather than sustainable operational improvement, increasing vulnerability if working capital reverses or macroeconomic stress intensifies.
Fresenius Medical Care’s full-year 2026 revenue guidance remains broadly flat despite Q1’s 4% organic growth, as management explicitly acknowledges that the TDAPA reimbursement tailwind — contributing approximately EUR 80 million in Q1 and expected to reverse into a significant headwind in H2 — will be offset by declining volumes and structural pressures, implying that the current earnings strength is artificial and unsustainable once the temporary benefit expires, leaving the business exposed to underlying volume stagnation.
Same-market treatment growth in the U.S. Care Delivery segment declined by 37 basis points in Q1 FY26, with management attributing only partial impact to severe weather and acknowledging persistent headwinds from mortality remaining above pre-pandemic levels, uncertain ACA subsidy impacts post-grace period, and ongoing clinic closures (64 already exited, targeting up to 100), suggesting that patient inflow challenges are structural and not merely cyclical, with no clear path to positive volume growth even as operational improvements roll out.
Care Enablement continues to face persistent and growing headwinds in China from volume-based procurement (VBP) and stricter tender requirements, with the segment’s organic revenue growth of 1% in Q1 FY26 being entirely dependent on strength outside China, while the company admitted that China represents 7–10% of Care Enablement sales and remains under pressure, with no clear timeline for re-entry into tenders or margin recovery, raising concerns about long-term viability of this growth pillar in a key emerging market.
Value-Based Care’s Q1 FY26 performance was bolstered by non-recurring prior-period contract true-ups and favorable premium rate effects, with management explicitly stating that revenue growth will “turn negative throughout the year” due to a change in accounting treatment for a large contract, and that the current profitability is unlikely to be sustained, signaling that the segment’s recent strength is a mirage driven by one-time items rather than organic momentum or scalable model validation.
The company’s operating cash flow increase of 39% in Q1 FY26 was driven primarily by favorable working capital management (EUR 133 million inflow, or nearly 60% of operating cash flow), with Martin Fischer acknowledging that adjusting for this line implies a 50% reduction in underlying operating cash flow, revealing that the apparent cash flow strength is temporary and reliant on short-term timing benefits rather than sustainable operational improvement, increasing vulnerability if working capital reverses or macroeconomic stress intensifies.